Investor Presentaiton

DS-2325 (KLK5 inhibitor) New clinical study Target Disease ■Netherton syndrome An autosomal recessive genetic disease affecting skin, hair and immune system - Caused by mutations in the SPINK5 gene, which encodes LEKTI, a serine protease inhibitor - Incidence is estimated at 1/200,000-1/300,000 births Development Stage Ph1 study started in June 2022 Randomized, placebo-controlled, double-blind study in healthy adults - Evaluate the safety, tolerability, and PK Mode of Action ■Skin of NS patient - - Desquamation - Inflammation DS-2325 (KLK5 inhibitor) KLK5 LEKTI (Loss-of-function mutations) Daiichi-Sankyo 35

View entire presentation